English
Deutsch
Italiano
Français
日本語
한국어
Services
China Registration for Life Sciences
Medical Devices & IVDs
Pharmaceutical Products
Cosmetics
Health Food & Supplements
Hong Kong Registration
CCC, CML & CEL
China Compulsory Certification (CCC)
China Manufacturing License / SELO
China Energy Label
Quality Control & Sourcing
Audits
Events
Trade Fairs & Conferences
Seminars
Webinars
News & Knowledge
Regulatory News
Medical Devices and IVDs
Cosmetics
Pharmaceuticals & DMF
CCC
Pressure Vessels
Whitepapers
FAQ – NMPA Registration – Medical Devices and IVDs
Newsletter Sign Up
Others
Publications
Online Shop
About us
Partners
Company Profile
Testimonials
Locations
Newsletter Sign Up
Contact
Home
News
NMPA Registration in China
Archive from category "Pharmaceuticals & DMF"
Page 6
Category: Pharmaceuticals & DMF
0
Cisema - Jacky
Thursday, 13 October 2022
/
Published in
Cosmetics
,
Medical Device
,
News
,
NMPA Registration in China
,
Pharmaceuticals & DMF
,
Webinars
Medtech, Cosmetics and Pharmaceuticals Webinars, Collaborations and Events Towards the End of the Year 2022
The medtech, cosmetics, and pharmaceutical webinars are presented by Cisema’s team of regulatory experts, sharing
0
Cisema - Jacky
Friday, 07 October 2022
/
Published in
News
,
NMPA Registration in China
,
Pharmaceuticals & DMF
ICH Q13 guidelines on continuous manufacturing in pharmaceuticals in China – draft for comments
ICH Q13 guidelines on continuous manufacturing in pharmaceuticals in China have been incorporated into a
0
Cisema - Jacky
Thursday, 06 October 2022
/
Published in
News
,
NMPA Registration in China
,
Pharmaceuticals & DMF
Draft guidelines for Communication on Real-World Evidence (RWE) to support drug registration applications
Real-World Evidence China: draft guidelines on communication for real world evidence to support drug registration
0
Cisema - Jacky
Wednesday, 07 September 2022
/
Published in
News
,
NMPA Registration in China
,
Pharmaceuticals & DMF
ICH E8 (R1) General Considerations for Clinical Studies have been approved in China
ICH E8 (R1) General Considerations for Clinical Studies and E14 Clinical Evaluation of QT/QTc Interval
3
4
5
6
7
8
9
TOP